Two studies found vedolizumab was more effective than a placebo as an induction and maintenance treatment for ulcerative colitis, and more likely to lead to remission in Crohn's disease. Researchers found adverse event rates were not different between vedolizumab and control groups in the UC trial but were higher among vedolizumab users in the Crohn's trial.

Related Summaries